Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Making the Most Out of Synapse: Searching for Codeine
Drug Insights
2 min read
Making the Most Out of Synapse: Searching for Codeine
7 March 2024
Codeine, a diminutive molecular compound, exerts its agonistic influence upon opioid receptors situated within the central nervous system.
Read →
Weekly Islatravir-Lenacapavir Combo Maintains Viral Control in Phase 2 Trial
Latest Hotspot
3 min read
Weekly Islatravir-Lenacapavir Combo Maintains Viral Control in Phase 2 Trial
7 March 2024
Gilead Sciences and Merck unveil preliminary results from stage two trial revealing that a weekly oral blend of Islatravir and Lenacapavir successfully sustained control over viral levels up to the 24-week mark.
Read →
Targeting the Amylin Receptor for Obesity Weight Reduction
Targeting the Amylin Receptor for Obesity Weight Reduction
7 March 2024
Islet Amyloid Polypeptide (IAPP), also known as amylin, is a peptide hormone composed of 37 amino acids, secreted by the pancreatic beta-cells.
Read →
Sandoz Obtains US Health Regulator's Green Light for Unique Denosumab Bioequivalents
Latest Hotspot
4 min read
Sandoz Obtains US Health Regulator's Green Light for Unique Denosumab Bioequivalents
7 March 2024
Sandoz announced that its products Wyost® and Jubbonti®, both containing denosumab-bbdz, have been approved by the US FDA.
Read →
Synapse Simplified: How to Find Clotrimazole Information
Drug Insights
2 min read
Synapse Simplified: How to Find Clotrimazole Information
7 March 2024
Clotrimazole, a diminutive molecule of pharmacological relevance, exerts its influence as an astoundingly powerful CYP51A1 inhibitor.
Read →
Innate Pharma Reveals Early Research on Nectin-4 Targeting Agent IPH45 at 2024 AACR Event
Latest Hotspot
3 min read
Innate Pharma Reveals Early Research on Nectin-4 Targeting Agent IPH45 at 2024 AACR Event
7 March 2024
Innate Pharma SA has declared that its pioneering research on the preclinical compound IPH45, a unique Antibody Drug Conjugate that targets Nectin-4 by inhibiting topoisomerase I.
Read →
AbbVie Explores New Target ChemR23 for the Treatment of Chronic Inflammation
AbbVie Explores New Target ChemR23 for the Treatment of Chronic Inflammation
7 March 2024
AbbVie, a US-based pharma company, partnered with French firm OSE Immunotherapeutics on Feb 28 to co-develop OSE-230, a new monoclonal antibody for chronic inflammation.
Read →
Pfizer's Clinical Advancements with Drug PF-08046052 Reported by LAVA
Latest Hotspot
3 min read
Pfizer's Clinical Advancements with Drug PF-08046052 Reported by LAVA
7 March 2024
LAVA has reported progress in clinical phase achievements by Pfizer with the drug PF-08046052, previously known as SGN-EGFRd2 or LAVA-1223.
Read →
A Complete Guide to Searching Estradiol on Synapse
Drug Insights
2 min read
A Complete Guide to Searching Estradiol on Synapse
7 March 2024
Estradiol (E2), a predominant female sex hormone and a member of the estrogen family, is responsible for regulating the menstrual and estrous cycles.
Read →
First Patient Treated in IPH6501 Trial for Relapsed/Refractory B-Cell NHL
Latest Hotspot
3 min read
First Patient Treated in IPH6501 Trial for Relapsed/Refractory B-Cell NHL
7 March 2024
Inborn Therapeutics: Initial Participant Treated in Early-to-Mid Stage Trial of IPH6501 for Recurrent or Resistant B-Cell Non-Hodgkin Lymphoma.
Read →
Using Synapse for Your Sulfamethoxazole Research: An Easy Guide
Drug Insights
2 min read
Using Synapse for Your Sulfamethoxazole Research: An Easy Guide
7 March 2024
Sulfamethoxazole was first approved in 1965 by FDA , it was first marketed by Roche and sold under the trade name Gantanol® in the US.
Read →
Promising Early Results for BI-1206 in Chinese Non-Hodgkin's Lymphoma Study by CASI Pharma
Latest Hotspot
3 min read
Promising Early Results for BI-1206 in Chinese Non-Hodgkin's Lymphoma Study by CASI Pharma
7 March 2024
CASI Pharma Announces Encouraging Early Results for BI-1206 in Managing Persistent Forms of Non-Hodgkin’s Lymphoma in Chinese Study.
Read →